Heatmap
Which measures hit which profiles
Every measure against every company profile. Select a column heading to add or remove that profile, or a measure to read it in full.
| Measure | Match | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Not relevant | Not relevant | Relevant | Not relevant | Relevant | Not relevant | Not relevant | Not relevant | Not relevant | Relevant | ||
| Relevant | Not relevant | Relevant | Not relevant | Relevant | Not relevant | Not relevant | Not relevant | Not relevant | Not relevant | ||
| Relevant | Not relevant | Relevant | Not relevant | Relevant | Not relevant | Not relevant | Not relevant | Not relevant | Not relevant | ||
| Not relevant | Not relevant | Relevant | Not relevant | Relevant | Not relevant | Not relevant | Not relevant | Relevant | Not relevant | ||
| Relevant | Relevant | Not relevant | Not relevant | Relevant | Not relevant | Not relevant | Not relevant | Not relevant | Not relevant | ||
| Not relevant | Not relevant | Not relevant | Not relevant | Not relevant | Not relevant | Not relevant | Not relevant | Relevant | Not relevant | ||
| Not relevant | Not relevant | Not relevant | Relevant | Relevant | Not relevant | Not relevant | Not relevant | Not relevant | Not relevant | ||
| Relevant | Not relevant | Relevant | Not relevant | Not relevant | Not relevant | Not relevant | Not relevant | Not relevant | Relevant | ||
| Not relevant | Not relevant | Not relevant | Relevant | Not relevant | Not relevant | Not relevant | Not relevant | Not relevant | Relevant | ||
| Not relevant | Relevant | Not relevant | Not relevant | Not relevant | Relevant | Not relevant | Not relevant | Relevant | Not relevant | ||
| Relevant | Relevant | Not relevant | Not relevant | Not relevant | Relevant | Relevant | Not relevant | Not relevant | Not relevant | ||
| Relevant | Relevant | Not relevant | Not relevant | Not relevant | Not relevant | Not relevant | Not relevant | Relevant | Not relevant | ||
| Relevant | Relevant | Not relevant | Not relevant | Relevant | Not relevant | Not relevant | Not relevant | Not relevant | Not relevant | ||
| Not relevant | Not relevant | Relevant | Not relevant | Not relevant | Not relevant | Not relevant | Relevant | Relevant | Relevant | ||
| Not relevant | Not relevant | Relevant | Not relevant | Not relevant | Not relevant | Not relevant | Relevant | Relevant | Relevant | ||
| Not relevant | Not relevant | Relevant | Not relevant | Not relevant | Not relevant | Not relevant | Relevant | Relevant | Relevant | ||
| Not relevant | Not relevant | Relevant | Not relevant | Relevant | Not relevant | Not relevant | Not relevant | Not relevant | Relevant | ||
| Measures per profile | 7 | 5 | 9 | 2 | 8 | 2 | 1 | 3 | 7 | 7 |
Point at or tab to a row or column heading for a one-line explanation.
- Relevant to your profile
- Relevant to another profile
- Relevant (no profile chosen)
- Not relevant
- Pharma Package
- Critical Medicines Act
- HTA Regulation
- Row colour shows the law
Selected measure
Open in OverviewPharma PackageRegulatory protection is reshuffled
- Today
- 8 years of data protection plus 2 years of market protection, with 1 extra year for a significant new indication.
- New rules
- 8 years of data protection plus 1 year of market protection (Directive Art 83). Market protection is extended by 12 months, once, if the medicine addresses an unmet medical need, or if a medicine with a new active substance meets one of three sets of conditions: a comparator trial in line with EMA scientific advice and filing in the EU first or within 90 days of the first filing outside the EU; a comparator trial and efficacy trials in more than one Member State; or, where a comparator trial is not possible, efficacy trials in more than one Member State and that early EU filing (Art 84(1)). One more year of market protection if a new indication with significant clinical benefit is authorised during data protection, granted once (Art 84(2)). Market protection cannot run more than 2 years past the end of data protection, or 3 with the new-indication year (Art 84(3)): at most 11 years in total, or 12 if an antimicrobial voucher adds a year of data protection. Applications submitted before 24 months after entry into force keep the old periods (Art 221(5)).
- What it means
- The baseline drops from 10 to 9 years. Getting back to 10 or 11 years depends on choices made during development and filing: comparator trials, where trials run, and how soon you file in the EU.
- Next step
- Map each asset against the extension routes now; they shape trial design and filing strategy.
Status Agreed text, not yet in force
Area Exclusivity & IP
Relevant to Biotech / originator, Authorised in the EU, In development
SourceDirective, Council position at first reading (ST 7106/26), Articles 83, 84, 85 and 221(5)Open text: source for Regulatory protection is reshuffled (PDF)
Last verified21 November 2026 · AI-assisted check against the official text, pending human legal review
Still to verify (1)
- Needs source: the current rules ('Today') are in Directive 2001/83/EC, Article 10, which has not been checked against the official text yet.
Pharma PackageEarlier generic filing, only after a failed supply request
- Today
- Generic and biosimilar applications can refer to the originator's data once the 8-year data protection period has ended.
- New rules
- A generic or biosimilar application can be validated and assessed from year 6 of the reference product's data protection, but only where a Member State has published that the originator did not meet its launch and supply request (Directive Art 59(5) to (7)). The generic still cannot be authorised before data protection ends.
- What it means
- This is not an automatic year-6 filing right, despite how it has often been reported. It follows from not meeting a Member State's supply request, so launch planning now also protects data exclusivity.
- Next step
- Originators: treat supply-request compliance as part of protecting exclusivity. Generics and biosimilars: watch Member State publications under Article 59(6) for early-filing opportunities.
Status Agreed text, not yet in force
Area Exclusivity & IP
Relevant to Generic or biosimilar, Biotech / originator, Authorised in the EU
SourceDirective, Council position at first reading (ST 7106/26), Article 59(5) to (7)Open text: source for Earlier generic filing, only after a failed supply request (PDF)
Last verified21 November 2026 · AI-assisted check against the official text, pending human legal review
Still to verify (2)
- Legal review: the founder brief and prototype described a general year-6 filing right; the Council text ties it to Article 59. Confirm this reading.
- Needs source: 'Today' wording (Directive 2001/83/EC, Article 10).
Pharma PackageWider, harmonised Bolar exemption
- Today
- The scope of the exemption varies between Member States.
- New rules
- Patents and supplementary protection certificates are not infringed by studies, trials and other activities carried out to obtain a marketing authorisation (including for generics, biosimilars, hybrids and variations), to run a health technology assessment, to obtain pricing and reimbursement approval, to meet related practical requirements, or to bid in public tenders as long as nothing is sold or marketed during the patent or certificate term. The exemption does not cover placing the product on the market (Directive Art 87).
- What it means
- Generics and biosimilars can finish authorisation, HTA, pricing and tender preparations before IP expiry and be ready to launch on day one.
- Next step
- Originators: revisit patent-expiry planning. Generics: define which activities are covered and how to document them.
Status Agreed text, not yet in force
Area Exclusivity & IP
Relevant to Generic or biosimilar, Biotech / originator, Authorised in the EU
SourceDirective, Council position at first reading (ST 7106/26), Article 87Open text: source for Wider, harmonised Bolar exemption (PDF)
Last verified21 November 2026 · AI-assisted check against the official text, pending human legal review
Still to verify (1)
- Needs source: 'Today' wording (current national variation in Bolar scope).
Pharma PackageLaunch and supply requests from Member States
- Today
- Launch timing is largely a commercial decision.
- New rules
- For a product still under regulatory protection or orphan exclusivity, a Member State can ask the holder to place it on its market and supply it to meet patients' needs. It can require one or more of: a valid pricing and reimbursement application, meeting procurement requirements, and a roll-out plan agreed with the Member State (Directive Art 59(1) to (3)). The request must be made within one year of the marketing authorisation (Art 59(4)). If the product has not been made available and continuously supplied within three years of the request, market protection, and any orphan exclusivity extension, no longer applies in that country (Art 59(5)). Member States can use this from 12 months after entry into force, for products authorised after entry into force (Art 222(2)).
- What it means
- Launch sequencing and pricing strategy now carry a protection risk, country by country. A failed request is also published, which lets generics file early (see "Earlier generic filing").
- Next step
- Build a country-by-country launch and supply plan you can show was made in good faith and with best efforts.
Status Agreed text, not yet in force
Area Supply & shortages
Relevant to Biotech / originator, Authorised in the EU, Orphan medicine
SourceDirective, Council position at first reading (ST 7106/26), Articles 59 and 222(2)Open text: source for Launch and supply requests from Member States (PDF)
Last verified21 November 2026 · AI-assisted check against the official text, pending human legal review
Still to verify (1)
- Needs source: 'Today' wording.
Pharma PackageShortage prevention plans and 6-month notice
- New rules
- Holders must keep an up-to-date shortage prevention plan for prescription medicines and for other medicines the Commission identifies (Regulation Art 121). They must notify the authorities at least 6 months before a temporary disruption expected to last more than two weeks, or before temporarily suspending marketing, and at least 12 months before permanently stopping marketing or withdrawing the authorisation (Art 120). These rules apply 6 months after entry into force (Art 187).
- What it means
- New planning, monitoring and reporting duties for every authorised prescription product, starting earlier than most of the package.
- Next step
- Check which products need a plan and set up an early-warning process between supply chain and regulatory teams.
Status Agreed text, not yet in force
Area Supply & shortages
Relevant to Authorised in the EU, Manufacturer, CDMO or API, Generic or biosimilar
SourceRegulation, Council position at first reading (ST 7105/26), Articles 120, 121 and 187Open text: source for Shortage prevention plans and 6-month notice (PDF)
Last verified21 November 2026 · AI-assisted check against the official text, pending human legal review
Still to verify (1)
- Needs source: Article 120 contains an exception to the 6-month notice that has not been summarised yet.
Pharma PackageOrphan market exclusivity is recalibrated
- Today
- 10 years of market exclusivity as standard.
- New rules
- 9 years as standard; 11 years for "breakthrough" orphan medicines, meaning there is no authorised medicine for the condition and the medicine brings a clinically relevant reduction in illness or deaths; 4 years for orphan medicines authorised on bibliographic data under Directive Article 14 (Regulation Arts 72 and 73). Exclusivity is extended by 12 months if a new indication for a different orphan condition is authorised at least two years before exclusivity ends. This can happen twice, does not apply to the 4-year tier, and rules out the separate new-indication year of market protection (Art 74). Several orphan authorisations for the same active substance share one exclusivity period (Art 73(3)). Similar products, including generics and biosimilars, can be filed and assessed in the last two years of exclusivity (Art 73(6)).
- What it means
- One year less as standard, with a longer tier for breakthrough products and room to earn up to two more years with new orphan indications.
- Next step
- Assess which tier each orphan asset can credibly reach, and plan new orphan indications early enough to be authorised two years before expiry.
Status Agreed text, not yet in force
Area Exclusivity & IP
Relevant to Orphan medicine
SourceRegulation, Council position at first reading (ST 7105/26), Articles 72, 73 and 74Open text: source for Orphan market exclusivity is recalibrated (PDF)
Last verified21 November 2026 · AI-assisted check against the official text, pending human legal review
Still to verify (1)
- Needs source: 'Today' wording (Regulation (EC) No 141/2000).
Pharma PackageTransferable voucher for priority antimicrobials
- New rules
- The Commission can grant a "priority antimicrobial" a transferable voucher worth 12 more months of data protection (Regulation Art 41). It can be used once, on one centrally authorised product, the holder's own or another company's. When used on another product, that must happen in the fifth or sixth year of that product's data protection, and only if its annual EU gross sales did not exceed EUR 490 million in any of its first four years (Art 42(1)). A voucher can be transferred once (Art 42(4)) and lapses if not used within five years of being granted (Art 43). To qualify, the antimicrobial must, among other conditions, be filed with EMA first or within 180 days of its first filing outside the EU (Art 41(4)). The scheme runs until 15 years after entry into force or until five vouchers have been granted, whichever comes first (Art 44), and applies from entry into force (Art 187).
- What it means
- With only five vouchers available, timing against competitors matters. Holders of mid-sized centrally authorised products in year five or six of protection are potential buyers.
- Next step
- Check eligibility early and track how many vouchers have already been granted.
Status Agreed text, not yet in force
Area Exclusivity & IP
Relevant to Antimicrobial, Authorised in the EU
SourceRegulation, Council position at first reading (ST 7105/26), Articles 41 to 44 and 187Open text: source for Transferable voucher for priority antimicrobials (PDF)
Last verified21 November 2026 · AI-assisted check against the official text, pending human legal review
Still to verify (1)
- Needs source: the prototype also mentioned an antimicrobial stewardship plan and an antimicrobial-resistance risk assessment; not yet checked against the text.
Pharma PackageFaster standard EMA review
- Today
- Standard assessment takes up to 210 days.
- New rules
- EMA's scientific committee must give its opinion within 180 days of receiving a valid application (Regulation Art 7(6); recital 22 describes the cut from 210 to 180 days).
- What it means
- Shorter time from submission to opinion; plan submission readiness and resourcing accordingly.
- Next step
- Update regulatory timelines and resourcing assumptions.
Status Agreed text, not yet in force
Area Approval process
Relevant to In development, Biotech / originator, Generic or biosimilar
SourceRegulation, Council position at first reading (ST 7105/26), Article 7(6) and recital 22Open text: source for Faster standard EMA review (PDF)
Last verified21 November 2026 · AI-assisted check against the official text, pending human legal review
Still to verify (1)
- Needs source: the prototype also mentioned a simpler internal structure at EMA.
Pharma PackageExpanded environmental risk assessment
- New rules
- Applicants must follow EMA's guidelines when preparing the environmental risk assessment, flag constituents that are endocrine-active or persistent, bioaccumulative, mobile or toxic, and include measures to limit emissions of listed pollutants (Directive Art 23). For antimicrobials, the assessment covers the risk of resistance developing in the environment across the whole manufacturing supply chain, use and disposal. Separate rules cover products authorised before 30 October 2005 (Art 24) and an EMA monograph system (Art 25).
- What it means
- More environmental data and risk-mitigation measures in new applications.
- Next step
- Add environmental studies to development plans early.
Status Agreed text, not yet in force
Area Approval process
Relevant to In development, Antimicrobial
SourceDirective, Council position at first reading (ST 7106/26), Articles 23 to 25Open text: source for Expanded environmental risk assessment (PDF)
Last verified21 November 2026 · AI-assisted check against the official text, pending human legal review
Still to verify (1)
- Needs source: what Articles 24 and 25 require in practice has not been summarised yet.
Critical Medicines ActStrategic projects for EU manufacturing
- New rules
- An EU manufacturing project is recognised as a strategic project if it creates, modernises or expands capacity for critical medicines, their active substances or key inputs, or rolls out a key enabling technology (CMA Art 5). Each Member State designates an authority that decides within 20 days of a request (Art 6). Strategic projects are in the public interest and get accelerated permitting where it exists (Art 7). Member States may prioritise funding for projects that address a supply-chain vulnerability, within State-aid rules (Art 15), and EU funding can come from programmes such as EU4Health, Horizon Europe and Digital Europe (Art 16). Companies that receive public support must prioritise supply to the EU market while the product is on the Union list of critical medicines (Arts 15(2) and 16). These rules also apply to orphan medicines (Art 2(2a)).
- What it means
- A route to faster permits and funding for new EU capacity, including active substance production, in exchange for EU supply priority.
- Next step
- If you plan EU capacity, assess eligibility and identify the designated authority in your country.
Status Agreed text, not yet in force
Area Industrial policy & procurement
Relevant to Manufacturer, CDMO or API, Manufacturing in the EU, Orphan medicine
SourceCritical Medicines Act, final compromise text (Council document ST 11059/26), Articles 2(2a), 5 to 7, 15 and 16Open text: source for Strategic projects for EU manufacturing (PDF)
Last verified21 November 2026 · AI-assisted check against the official text, pending human legal review
Still to verify (1)
- Check: the prototype linked EU funding to the 2028-2034 budget; the agreed text refers to the 2021-2027 programmes. Confirm what applies when the Act takes effect.
Critical Medicines ActSupply resilience counts in public tenders
- New rules
- When buying critical medicines, public buyers must apply "resilience requirements" that diversify supply sources and reward reliable suppliers, through selection criteria, technical specifications, award criteria or contract clauses (CMA Art 18(1)). Where a critical medicine depends heavily on one or a few non-EU countries, buyers must favour EU manufacturing, either by reserving a lot of at least 50% of the volume for EU-made supply in multi-winner tenders or by scoring that rewards EU manufacturing (Art 18(2)). Import, repackaging, labelling and testing alone do not count as EU manufacturing. Buyers may exceptionally skip these rules, for example when only one supplier exists, a recent tender drew no suitable bids, or costs would be disproportionate (Art 18(5)). The requirements apply to tenders launched after the Act starts to apply (Art 31).
- What it means
- Offers relying on a single non-EU source may score worse; EU-based or diversified supply may gain an advantage.
- Next step
- Map your supply chains for critical medicines and document diversification and EU manufacturing steps.
Status Agreed text, not yet in force
Area Industrial policy & procurement
Relevant to Generic or biosimilar, Manufacturer, CDMO or API, Supply from outside the EU, Manufacturing in the EU
SourceCritical Medicines Act, final compromise text (Council document ST 11059/26), Articles 18 and 31Open text: source for Supply resilience counts in public tenders (PDF)
Last verified21 November 2026 · AI-assisted check against the official text, pending human legal review
Still to verify (1)
- Needs source: timing and content of Commission guidelines on Article 18 (founder brief).
Critical Medicines ActJoint procurement and orphan medicines in scope
- Today
- Nine Member States are needed to ask the Commission to procure on their behalf.
- New rules
- When five or more Member States ask, the Commission must run a procurement on their behalf unless it gives substantiated reasons not to (CMA Art 22(1)). This covers critical medicines with an identified supply-chain vulnerability or a recommendation for common procurement, and medicines of common interest. Orphan medicines are included (Art 2(2a)).
- What it means
- Larger, centralised tenders; orphan developers gain access to these routes.
- Next step
- Prepare to bid for multi-country tenders; orphan developers should check eligibility.
Status Agreed text, not yet in force
Area Industrial policy & procurement
Relevant to Generic or biosimilar, Manufacturer, CDMO or API, Orphan medicine
SourceCritical Medicines Act, final compromise text (Council document ST 11059/26), Articles 2(2a) and 22Open text: source for Joint procurement and orphan medicines in scope (PDF)
Last verified21 November 2026 · AI-assisted check against the official text, pending human legal review
Still to verify (1)
- Needs source: 'Today' threshold of nine Member States (founder brief).
Critical Medicines ActContingency stocks become more transparent
- New rules
- Member States' contingency-stock requirements must be targeted, proportionate and transparent and must not harm other Member States (CMA Art 20). Member States must inform the Critical Medicines Coordination Group when they plan, change or impose such requirements, and EMA runs a digital platform showing them (Art 20a(1) and (3)). Sharing stock data for reallocation stays within the voluntary solidarity mechanism and happens on request, where reasonably possible (Art 20a(4)). The Commission will issue EU guidelines on contingency stocks (Art 20(2c)).
- What it means
- Stockpiling rules stay national but become visible across the EU. Supply planning for critical medicines may need to cover several countries' requirements at once.
- Next step
- Map contingency-stock requirements in your key markets and build them into supply planning.
Status Agreed text, not yet in force
Area Supply & shortages
Relevant to Authorised in the EU, Manufacturer, CDMO or API, Generic or biosimilar
SourceCritical Medicines Act, final compromise text (Council document ST 11059/26), Articles 20 and 20aOpen text: source for Contingency stocks become more transparent (PDF)
Last verified21 November 2026 · AI-assisted check against the official text, pending human legal review
HTA RegulationJoint clinical assessment replaces duplicate national reviews
- Today
- Each Member State ran its own, often overlapping, clinical assessment.
- New rules
- One EU-level joint clinical assessment of relative clinical effectiveness, run alongside EMA's review. It covers new active substances for cancer and all advanced therapy medicinal products (ATMPs) from 12 January 2025, orphan medicines from 13 January 2028, and all other medicines in scope from 13 January 2030 (HTA Regulation Art 7(2)). Member States must give due consideration to the joint report in their national assessments (Art 13(1)), while pricing and reimbursement stay national (Art 1(2)).
- What it means
- Expect one EU clinical dossier instead of many national ones, but national pricing and economic evaluation continue.
- Next step
- Identify which phase each asset falls into and plan the clinical evidence for the joint dossier, not only for EMA.
Status In force
Area Market access & HTA
Relevant to Biotech / originator, In development, Orphan medicine, Oncology or cell/gene therapy (ATMP)
SourceRegulation (EU) 2021/2282, Articles 1(2), 7(2) and 13(1)Open text: source for Joint clinical assessment replaces duplicate national reviews (PDF)
Last verified21 November 2026 · AI-assisted check against the official text, pending human legal review
Still to verify (1)
- Needs source: first joint clinical assessment report published in June 2026 (founder brief).
HTA RegulationMember States set the questions your dossier must answer
- New rules
- Member States' needs are pooled into one assessment scope covering the patient population, intervention, comparators and health outcomes, known as PICO (HTA Regulation Art 8(6)). If the developer's dossier is late or incomplete, the joint assessment is discontinued and a statement is published (Art 10(6)).
- What it means
- Expect more comparators and subgroups than a single-market plan would need.
- Next step
- Plan evidence for several comparators early and prepare for a short dossier window.
Status In force
Area Market access & HTA
Relevant to Biotech / originator, In development, Orphan medicine, Oncology or cell/gene therapy (ATMP)
SourceRegulation (EU) 2021/2282, Articles 8(6) and 10(6)Open text: source for Member States set the questions your dossier must answer (PDF)
Last verified21 November 2026 · AI-assisted check against the official text, pending human legal review
Still to verify (1)
- Needs source: the prototype cited a consultancy analysis saying developers have up to 100 days to submit the dossier. Check against the Commission's implementing act on procedures.
HTA RegulationEarly joint scientific advice
- New rules
- Developers can request a joint scientific consultation while their clinical studies are still being planned, for products likely to undergo a joint clinical assessment. It covers study design, including comparators, interventions, outcomes and patient populations, and can run in parallel with EMA scientific advice. The outcome is not legally binding (HTA Regulation Arts 16 and 17). Request periods and the planned number of consultations are published in advance (Art 17(3)).
- What it means
- A way to test your evidence plan against what Member States will ask for before pivotal studies are fixed. Places are limited per request period.
- Next step
- Decide early whether to apply for assets that will fall under joint assessment.
Status In force
Area Market access & HTA
Relevant to Biotech / originator, In development, Orphan medicine, Oncology or cell/gene therapy (ATMP)
SourceRegulation (EU) 2021/2282, Articles 16 and 17Open text: source for Early joint scientific advice (PDF)
Last verified21 November 2026 · AI-assisted check against the official text, pending human legal review
HTA RegulationJoint assessment, national pricing and launch rules interact
- New rules
- The joint report feeds national assessments while pricing and reimbursement stay national (HTA Regulation Arts 1(2) and 13). Separately, under the Pharma Package a Member State can require the holder of a protected product to file a valid pricing and reimbursement application (Directive Art 59(2)).
- What it means
- Evidence timing, national filings and launch sequencing need to be planned together. This link is our reading of the two laws, not a rule written in either.
- Next step
- Build one plan covering the joint dossier, national submissions and launch obligations.
Status In force
Area Market access & HTA
Relevant to Biotech / originator, Authorised in the EU, In development
SourceRegulation (EU) 2021/2282, Articles 1(2) and 13, read with Directive (ST 7106/26) Article 59(2)Open text: source for Joint assessment, national pricing and launch rules interact (PDF)
Last verified21 November 2026 · AI-assisted check against the official text, pending human legal review
Still to verify (1)
- Interpretation, not a rule in either text: confirm with legal review.